Data analysis from two clinical trial revealed that the success of treatment is associated with mucosal healing in patients with moderately active ulcerative colitis (UC) who received either 2.4 or 4.8 grams of mesalamine per day.
The said combined data analysis has been presented by
Find more details of the clinical data at the P&G press release. 
A product of Procter and Gamble (NYSE: PG), mesalamine (Asacol®) Delayed-Release Tablets 400 mg is indicated for the treatment of mildly to moderately active UC (the indicated dosage is two 400 mg tablets tid for 6 weeks) and for the maintenance of remission of UC (the indicated dosage is 1.6 g/day in divided doses).
Comment Preview